The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Oncolytic viral therapies – the clinical experience
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
Natural fibres as reinforcement in polylactic acid (PLA) composites
Oksman, K., Skrifvars, M., & Selin, J.-F. (2003) · Composites Science and Technology · doi:10.1016/s0266-3538(03)00103-9 · Cited by 1,565
Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., et al. (2000) · Nature Medicine · doi:10.1038/78638 · Cited by 1,101
Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant
Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., & Coen, D. M. (1991) · Science · doi:10.1126/science.1851332 · Cited by 1,050
Self-citationMarkert, J. M., Medlock, M. D., Rabkin, S. D., Gillespie, G. Y., Todo, T., Hunter, W. D., Palmer, C. A., Feigenbaum, F., Tornatore, C., Tufaro, F., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301205 · Cited by 976
Self-citationHeise, C., Sampson-Johannes, A., Williams, A., Mccormick, F., Von Hoff, D. D., & Kirn, D. H. (1997) · Nature Medicine · doi:10.1038/nm0697-639 · Cited by 940
Reovirus Therapy of Tumors with Activated Ras Pathway
Coffey, M. C., Strong, J. E., Forsyth, P. A., & Lee, P. W. K. (1998) · Science · doi:10.1126/science.282.5392.1332 · Cited by 750
Rampling, R., Cruickshank, G., Papanastassiou, V, Nicoll, J., Hadley, D., Brennan, D., Petty, R., MacLean, A., Harland, J., McKie, E., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301184 · Cited by 598
Nemunaitis, J., Khuri, F., Ganly, I., Arseneau, J., Posner, M., Vokes, E., Kuhn, J., McCarty, T., Landers, S., Blackburn, A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.289 · Cited by 471
Chiocca, E. A., Abbed, K. M., Tatter, S., Louis, D. N., Hochberg, F. H., Barker, F., Kracher, J., Grossman, S. A., Fisher, J. D., Carson, K., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.021 · Cited by 436
Pecora, A. L., Rizvi, N., Cohen, G. I., Meropol, N. J., Sterman, D., Marshall, J. L., Goldberg, S., Gross, P., O’Neil, J. D., Groene, W. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.042 · Cited by 385
Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity
O'Shea, C. C., Johnson, L., Bagus, B., Choi, S., Nicholas, C., Shen, A., Boyle, L., Pandey, K., Soria, C., Kunich, J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.11.012 · Cited by 372
Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma
Mastrangelo, M. J., Maguire, H. C., Eisenlohr, L. C., Laughlin, C. E., Monken, C. E., McCue, P. A., Kovatich, A. J., & Lattime, E. C. (1999) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700066 · Cited by 353
Harrow, S., Papanastassiou, V, Harland, J., Mabbs, R., Petty, R., Fraser, M., Hadley, D., Patterson, J., Brown, S. M., & Rampling, R. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302289 · Cited by 342
Papanastassiou, V, Rampling, R., Fraser, M., Petty, R., Hadley, D., Nicoll, J., Harland, J., Mabbs, R., & Brown, M. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301664 · Cited by 328
Mulvihill, S., Warren, R., Venook, A., Adler, A., Randlev, B., Heise, C., & Kirn, D. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301398 · Cited by 299
p53 Status Does Not Determine Outcome of E1B 55-Kilodalton Mutant Adenovirus Lytic Infection
Goodrum, F. D., & Ornelles, D. A. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9479-9490.1998 · Cited by 289
Nemunaitis, J., Cunningham, C., Buchanan, A., Blackburn, A., Edelman, G., Maples, P., Netto, G., Tong, A., Randlev, B., Olson, S., et al. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301424 · Cited by 283
Reid, T., Galanis, E., Abbruzzese, J., Sze, D., Andrews, J., Romel, L., Hatfield, M., Rubin, J., & Kirn, D. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301512 · Cited by 243
Prodrug activation enzymes in cancer gene therapy
Aghi, M. K., Hochberg, F. H., & Breakefield, X. O. (2000) · The Journal of Gene Medicine · doi:10.1002/(sici)1521-2254(200005/06)2:3<148::aid-jgm105>3.0.co;2-q · Cited by 188
Self-citation(2002) · Human Gene Therapy · doi:10.1089/10430340152712629 · Cited by 174
MacKay, J. A., Deen, D. F., & Szoka, F. C. (2005) · Brain Research · doi:10.1016/j.brainres.2004.12.007 · Cited by 172
Intralesional injection of herpes simplex virus 1716 in metastatic melanoma
MacKie, R. M., Stewart, B., & Brown, S. M. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04048-4 · Cited by 171
Phase I–II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas
Galanis, E., Okuno, S. H., Nascimento, A. G., Lewis, B. D., Lee, R. A., Oliveira, A. M., Sloan, J. A., Atherton, P., Edmonson, J. H., Erlichman, C., et al. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302436 · Cited by 170
Kramm, C. M., Chase, M., Herrlinger, U., Jacobs, A., Pechan, P. A., Rainov, N. G., Sena-Esteves, M., Aghi, M., Barnett, F. H., Chiocca, E. A., et al. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.17-2057 · Cited by 167
Self-citationGroot-Wassink, T., Aboagye, E. O., Glaser, M., Lemoine, N. R., & Vassaux, G. (2002) · Human Gene Therapy · doi:10.1089/104303402760293565 · Cited by 165
Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides
Peng, K.-W., Facteau, S., Wegman, T., O'Kane, D., & Russell, S. J. (2002) · Nature Medicine · doi:10.1038/nm0502-527 · Cited by 162
A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function.
Mohr, I., & Gluzman, Y. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00853.x · Cited by 157
Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer
Hamid, O., Varterasian, M. L., Wadler, S., Hecht, J. R., Benson, A. B., Galanis, E., Uprichard, M. J., Omer, C. A., Bycott, P. W., Hackman, R. C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.114 · Cited by 146
Lorence, R. M., Rood, P. A., & Kelley, K. W. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.16.1305 · Cited by 145
Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma
Habib, N. A., Salama, H., Median, A. A. E. L. A., et al. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700431 · Cited by 127
E1B-Deleted Adenovirus ( dl 1520) Gene Therapy for Patients with Primary and Secondary Liver Tumors
Habib, N. A., Sarraf, C., Mitry, R. R., et al. (2001) · Human Gene Therapy · doi:10.1089/10430340150218369 · Cited by 117
DIVISION OF MICROBIOLOGY: PRESENT STATUS OF ONCOLYTIC VIRUS STUDIES*
Southam, C. M. (1960) · Transactions of the New York Academy of Sciences · doi:10.1111/j.2164-0947.1960.tb00739.x · Cited by 115
Batliwalla, F., Bateman, B. A., Serrano, D., et al. (1998) · Molecular Medicine · doi:10.1007/bf03401771 · Cited by 114
Mukherjee, S., Haenel, T., Himbeck, R. P., Scott, B., Ramshaw, I. A., Lake, R., Harnett, G. B., Phillips, P. A., Morey, S., Smith, D. W., et al. (2000) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700133 · Cited by 111
Brown, S. M., MacLean, A. R., McKie, E. A., & Harland, J. (1997) · Journal of Virology · doi:10.1128/jvi.71.12.9442-9449.1997 · Cited by 109
Nemunaitis, J. J., Cunningham, C., Tong, A. W., Post, L. E., Netto, G. J., Paulson, A. S., Rich, D., Blackburn, A., Sands, B. E., Gibson, B., et al. (2003) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700585 · Cited by 90
Wu, J. T. K. (2003) · Bulletin of Mathematical Biology · doi:10.1016/j.bulm.2003.08.016 · Cited by 87
Morley, S. E., MacDonald, G., Kirn, D. H., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0443 · Cited by 39
Intracerebral recombinant HSV-1 vector does not reactivate latent HSV-1
Wang, Q., Guo, J. P., & Jia, W. W.-G. (1997) · Gene Therapy · doi:10.1038/sj.gt.3300535 · Cited by 34
Cited by
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
History of Oncolytic Viruses: Genesis to Genetic Engineering
Kelly, E., & Russell, S. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300108 · Cited by 763
Engineering targeted viral vectors for gene therapy
Waehler, R., Russell, S. J., & Curiel, D. T. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2141 · Cited by 687
Nonviral cancer gene therapy: Delivery cascade and vector nanoproperty integration
Zhou, Z., Liu, X., Zhu, D., Wang, Y., Zhang, Z., Zhou, X., Qiu, N., Chen, X., & Shen, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.021 · Cited by 379
Wakimoto, H., Kesari, S., Farrell, C. J., Curry, W. T., Zaupa, C., Aghi, M., Kuroda, T., Stemmer-Rachamimov, A., Shah, K., Liu, T.-C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3886 · Cited by 361
Self-citation
Metadata
- Authors
- Aghi, M., & Martuza, R. L.
- Venue
- Oncogene
- Published
- 2005-11-21
- Volume
- 24
- Issue
- 52
- Pages
- 7802-7816
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2028074588
- Cited by
- 288
- References
- 41
- FWCI
- 11.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.